MX2023006434A - Inhibidores de quinasa y usos de los mismos. - Google Patents

Inhibidores de quinasa y usos de los mismos.

Info

Publication number
MX2023006434A
MX2023006434A MX2023006434A MX2023006434A MX2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
compounds
methods
kinases
compositions
Prior art date
Application number
MX2023006434A
Other languages
English (en)
Spanish (es)
Inventor
Chen Chen
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of MX2023006434A publication Critical patent/MX2023006434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023006434A 2020-12-16 2021-12-16 Inhibidores de quinasa y usos de los mismos. MX2023006434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063126364P 2020-12-16 2020-12-16
PCT/US2021/063724 WO2022133040A1 (en) 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2023006434A true MX2023006434A (es) 2023-06-13

Family

ID=79425572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006434A MX2023006434A (es) 2020-12-16 2021-12-16 Inhibidores de quinasa y usos de los mismos.

Country Status (9)

Country Link
US (1) US20240083844A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263501A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023554391A (cg-RX-API-DMAC10.html)
KR (1) KR20230144529A (cg-RX-API-DMAC10.html)
CN (1) CN117083265A (cg-RX-API-DMAC10.html)
AU (1) AU2021401282A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179325A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023006434A (cg-RX-API-DMAC10.html)
WO (1) WO2022133040A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116356017A (zh) * 2022-12-12 2023-06-30 南京腾辰生物科技有限公司 一种甲状腺肿瘤良恶性早期诊断标志物及其应用
WO2025184877A1 (zh) * 2024-03-07 2025-09-12 中国医学科学院基础医学研究所 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用
WO2026064501A1 (en) * 2024-09-18 2026-03-26 The University Of Chicago Reversible and irreversible kinome probes and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444866T3 (es) * 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
GB0812913D0 (en) * 2008-07-15 2008-08-20 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2814617C (en) * 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
WO2012055953A1 (en) * 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
JP2015517574A (ja) * 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
WO2019006548A1 (en) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF

Also Published As

Publication number Publication date
JP2023554391A (ja) 2023-12-27
EP4263501A1 (en) 2023-10-25
WO2022133040A1 (en) 2022-06-23
KR20230144529A (ko) 2023-10-16
CA3179325A1 (en) 2022-06-23
US20240083844A1 (en) 2024-03-14
CN117083265A (zh) 2023-11-17
AU2021401282A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12022552739A1 (en) Fused tricyclic kras inhibitors
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
MY210070A (en) Heterocyclic compounds as immunomodulators
PH12019501350B1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12014501355B1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12021552579A1 (en) Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
UA95934C2 (ru) Производные пиридиазинона для лечения опухолей
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12021552395A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
PH12020551853A1 (en) Axl kinase inhibitors and use of the same
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
JOP20170108A1 (ar) مثبطات معزز نظير zeste 2
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
GEAP202516670A (en) Tricyclic triazolo compounds as dgk inhibitors
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
PH12021552110A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.